Correlation Between Oracle and IShares Genomics

Can any of the company-specific risk be diversified away by investing in both Oracle and IShares Genomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oracle and IShares Genomics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oracle and iShares Genomics Immunology, you can compare the effects of market volatilities on Oracle and IShares Genomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oracle with a short position of IShares Genomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oracle and IShares Genomics.

Diversification Opportunities for Oracle and IShares Genomics

-0.16

Correlation Coefficient

Oracle  IShares Genomics

Good diversification

The 3 months correlation between Oracle and IShares is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Oracle and iShares Genomics Immunology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on iShares Genomics Imm and Oracle is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oracle are associated (or correlated) with IShares Genomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of iShares Genomics Imm has no effect on the direction of Oracle i.e., Oracle and IShares Genomics go up and down completely randomly.

Pair Corralation between Oracle and IShares Genomics

Given the investment horizon of 90 days Oracle is expected to generate 1.26 times more return on investment than IShares Genomics. However, Oracle is 1.26 times more volatile than iShares Genomics Immunology. It trades about 0.19 of its potential returns per unit of risk. iShares Genomics Immunology is currently generating about -0.05 per unit of risk. If you would invest  16,959  in Oracle on September 5, 2024 and sell it today you would earn a total of  1,330  from holding Oracle or generate 7.84% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Oracle  vs.  iShares Genomics Immunology

Oracle

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Oracle are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite abnormal fundamental indicators, Oracle disclosed solid returns over the last few months and may actually be approaching a breakup point.

iShares Genomics Imm

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days iShares Genomics Immunology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, IShares Genomics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Oracle and IShares Genomics

The main advantage of trading using opposite Oracle and IShares Genomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oracle position performs unexpectedly, IShares Genomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IShares Genomics will offset losses from the drop in IShares Genomics' long position.

The idea behind Oracle and iShares Genomics Immunology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.